Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Optomed

4.00 EUR

+9.15 %

5,636 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
+9.15 %
+5.97 %
+10.36 %
-0.87 %
-9.20 %
-6.00 %
-10.83 %
-40.28 %
-12.77 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
85.71M EUR
Turnover
537.54K EUR
P/E (adj.) (25e)
-12.49
EV/EBIT (adj.) (25e)
-15.64
P/B (25e)
3.66
EV/S (25e)
4.79
Dividend yield-% (25e)
-
Coverage
Recommendation
Buy
Target price
4.80 EUR
Updated
17.12.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2
2026

Annual report '25

6.5
2026

Interim report Q1'26

8.5
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Optomed modtager internationalt anerkendt cybersikkerhedscertifikat
Analyst Comment1/21/2026, 3:44 PM by
Juha Kinnunen

Optomed modtager internationalt anerkendt cybersikkerhedscertifikat

Optomed
Press release1/21/2026, 9:00 AM

Optomed Oyj: Optomed Achieves ISO 27001 Certification for Information Security Management Systems

Optomed
Press release1/12/2026, 7:00 AM

Optomed Oyj: Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12/12/2025, 1:45 PM

Optomed Oyj: New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

Optomed
Regulatory press release12/10/2025, 8:00 PM

Optomed Oyj: Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

Optomed
Press release11/7/2025, 7:48 AM

Redeye: Optomed Q3 (Review) - Solid growth with a positive devices segment development

Optomed
Regulatory press release11/6/2025, 7:00 AM

Optomed Oyj: Optomed Plc: Interim Report, January - September 2025

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Myllylä

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Piila

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Himberg

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Knuutti

Optomed
Regulatory press release9/23/2025, 6:00 AM

Optomed Oyj: Optomed's Board has resolved upon a new option plan

Optomed
Regulation of medical devices and diagnostics in Europe
Analyst Comment9/19/2025, 5:18 AM by
Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

BioretecAiforia TechnologiesNexstimBiohitOptomedRevenio GroupModulightDetection TechnologyNightingale HealthBittium
Regulatory press release9/9/2025, 6:30 AM

Optomed Oyj: Composition of Optomed's Nomination Board

Optomed
Classification of medical devices and regulatory processes in the United States
Analyst Comment9/8/2025, 9:56 AM by
Antti Siltanen

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

BioretecNexstimOptomedRevenio GroupModulightBittiumDetection Technology
Press release8/8/2025, 1:30 PM

Redeye: Optomed Q2 - Soft Q2 sales raises the stakes for H2 recovery

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Wen

Optomed
Forum discussions
“It’s incredibly rewarding to see AEYE-DS being adopted so quickly and efficiently!” Says the founder & CEO of Optomed’s AI partner AEYE Health
1 hour ago
by Choyoba_Capital
14
Congratulations to all shareholders​:bottle_with_popping_cork:!! This creates significant belief in the AI narrative!
1 hour ago
by Tobias
7
Somewhat tongue-in-cheek, I predict that either Optomed won’t report or link this news on its own channels at all, or they’ll rush to announce that this has nothing to do with Optomed.
1 hour ago
by Bob Fleming
5
Waiting for a positive profit warning? There’s a promise of a better tomorrow in the air and even of hitting the acceleration lane?
41 minutes ago
by Pekka
4
The team at Optomed must have firmly believed in this, or known, given that extra money was spent on building up inventory last spring and summer.
9 minutes ago
3
Isn’t this an early indication of moving into a rapid growth phase? It’s a good time for building a position. By the time of a positive profit warning, the growth will have already materialized. A great year expected, I would assume.
1 minute ago
by Jummijammi2
1
There’s probably no announcement coming. They’ll cite the proximity of the quarterly report and counting fingers and toes. Regardless, fellow investors have found a lot of positives for Optomed. The company is silent; who knows why.
10 minutes ago
by Haukiranta
1
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.